# Aclaris Therapeutics, Inc. clinical trials: 34 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials with Aclaris Therapeutics, Inc. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Aclaris Therapeutics, Inc.: 34 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/aclaris-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07935590 | Study of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical... | Aclaris Therapeutics, Inc. | Phase 2 | Recruiting | Lichen Planus | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935590) |
| June 10, 2025 | NCT07011706 | ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis | Aclaris Therapeutics, Inc. | Phase 2 | Active not recruiting | Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011706) |
| September 5, 2024 | NCT06585202 | Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Atopic Dermatitis | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06585202) |
| August 23, 2022 | NCT05511519 | Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis | Aclaris Therapeutics, Inc. | Phase 2 | Terminated | Psoriatic Arthritis | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05511519) |
| June 27, 2022 | NCT05432596 | Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Atopic Dermatitis | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05432596) |
| March 15, 2022 | NCT05279417 | ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA) | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Rheumatoid Arthritis | 251 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05279417) |
| January 31, 2022 | NCT05216224 | ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Hidradenitis Suppurativa | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05216224) |
| October 22, 2020 | NCT04598269 | Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Atopic Dermatitis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04598269) |
| August 24, 2020 | NCT04524858 | Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) | Aclaris Therapeutics, Inc. | Phase 2 | Terminated | Cryopyrin-Associated Periodic Syndrome | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04524858) |
| January 30, 2020 | NCT04247815 | Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Rheumatoid Arthritis | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04247815) |
| January 23, 2019 | NCT03812510 | Safety Study of A-101 Topical Solution for the Treatment of Common Warts | Aclaris Therapeutics, Inc. | Phase 3 | Completed | Common Wart | 426 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03812510) |
| November 30, 2018 | NCT03759340 | ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) | Aclaris Therapeutics, Inc. | Phase 2 | Terminated | Alopecia Areata, Alopecia Universalis, Alopecia Totalis | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03759340) |
| October 2, 2018 | NCT03691831 | A Study of A-101 Topical Solution for the Treatment of Common Warts | Aclaris Therapeutics, Inc. | Phase 3 | Completed | Common Wart | 502 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03691831) |
| September 27, 2018 | NCT03687372 | Study of A-101 Topical Solution for the Treatment of Common Warts | Aclaris Therapeutics, Inc. | Phase 3 | Completed | Common Wart | 503 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03687372) |
| July 20, 2018 | NCT03594227 | ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Alopecia | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03594227) |
| July 13, 2018 | NCT03585296 | A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Atopic Dermatitis | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03585296) |
| June 11, 2018 | NCT03551821 | Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Alopecia Areata, Alopecia Totalis, Alopecia Universalis | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03551821) |
| April 12, 2018 | NCT03495817 | A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Androgenetic Alopecia | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03495817) |
| April 4, 2018 | NCT03487588 | An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses | Aclaris Therapeutics, Inc. | Phase 4 | Completed | Seborrheic Keratosis | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03487588) |
| March 19, 2018 | NCT03468855 | A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Vitiligo | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03468855) |
| December 21, 2017 | NCT03380390 | Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea | Aclaris Therapeutics, Inc. | Phase 4 | Completed | Rosacea | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03380390) |
| November 28, 2017 | NCT03354637 | A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata | Aclaris Therapeutics, Inc. | Phase 2 | Terminated | Alopecia Areata | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03354637) |
| October 20, 2017 | NCT03315689 | Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Alopecia Universalis (AU), Alopecia Totalis (AT) | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03315689) |
| September 11, 2017 | NCT03278028 | A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Common Wart | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03278028) |
| July 21, 2017 | NCT03224598 | A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra | Aclaris Therapeutics, Inc. | Phase 2 | Completed | Dermatosis Papulosa Nigra | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03224598) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1/2 | 1 |
| Phase 2 | 25 |
| Phase 3 | 6 |
| Phase 4 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 28 |
| Terminated | 4 |
| Active not recruiting | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Keratosis, Seborrheic | 8 |
| Warts | 6 |
| Dermatitis, Atopic | 5 |
| Alopecia Areata | 3 |
| Alopecia universalis | 3 |
| Arthritis | 3 |
| Dermatitis | 2 |
| Eczema | 2 |
| Alopecia | 2 |
| Arthritis, Rheumatoid | 2 |
| Dermatosis Papulosa Nigra | 1 |
| Cryopyrin-Associated Periodic Syndromes | 1 |
| Skin Diseases, Eczematous | 1 |
| Skin Diseases | 1 |
| Hidradenitis Suppurativa | 1 |
| Hidradenitis | 1 |
| Vitiligo | 1 |
| Lichen Planus | 1 |
| Lichen Planus, Oral | 1 |
| Rosacea | 1 |
| Arthritis, Psoriatic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Kosher restaurants in the United States](https://specstream.ai/data/businesses/kosher-restaurants/united-states)
- [Aircraft parts suppliers in the United States](https://specstream.ai/data/businesses/aircraft-parts-suppliers/united-states)
- [Indian restaurants in the United States](https://specstream.ai/data/businesses/indian-restaurants/united-states)
- [Waterproofing contractors in the United States](https://specstream.ai/data/businesses/waterproofing-contractors/united-states)
- [Health food restaurants in the United States](https://specstream.ai/data/businesses/health-food-restaurants/united-states)
- [Tree services in the United States](https://specstream.ai/data/businesses/tree-services/united-states)
